Fludarabine/rituximab combined with escalating doses of lenalidomide in untreated chronic lymphocytic leukemia (CLL) – a dose-finding study with escalating starting dose of lenalidomide and concomitant evaluation of safety and efficacy

Trial Profile

Fludarabine/rituximab combined with escalating doses of lenalidomide in untreated chronic lymphocytic leukemia (CLL) – a dose-finding study with escalating starting dose of lenalidomide and concomitant evaluation of safety and efficacy

Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Lenalidomide (Primary) ; Fludarabine; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Pharmacogenomic
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 May 2016 Status changed from active, no longer recruiting to completed.
    • 16 Jun 2015 Planned End Date changed from 1 Mar 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top